Allergy Therapeutics' Worthing Facility Receives Certificate of GMP Compliance - - BioPharm International

ADVERTISEMENT

Allergy Therapeutics' Worthing Facility Receives Certificate of GMP Compliance


Allergy Therapeutics, a pharmaceutical company specialized in allergy vaccination, announced that its Worthing facility has received its Certificate of GMP Compliance following recent inspection by the MHRA.

During the past seven years, more than £10 million has been invested in the upgrade of this injectables facility. The facility has the capacity to further increase output and operating efficiencies, with more than 210,000 allergy vaccines and diagnostic tests manufactured at this site each year and over 95% of sales made overseas. In the past 12 months, products have been supplied to new markets including the Baltic States and New Zealand.

Allergy Therapeutics employs around 200 people in Worthing and is proud of it trading heritage, spanning nearly 80 years.

Source: Allergy Therapeutics

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines

Click here